Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Market Research report - Pipeline Review, H2 2017

"The Latest Research Report Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

About Collagenase 3 Market

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)-Collagenase-3 (MMP13) is a member of the matrix metalloproteinase (MMP) family of neutral endopeptidases. It plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN, wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification.

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 4 and 1 respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Infectious Disease, Respiratory and Toxicology which include indications Osteoarthritis, Allergic Asthma, Alphavirus Infections, Arthralgia, Arthritis, Chemotherapy Induced Peripheral Neuropathy, Chikungunya Fever, Congestive Heart Failure (Heart Failure), Edema, Myocardial Infarction, Osteoarthritis Pain and Seasonal Allergic Rhinitis.

Request For Sample Report @ https://www.marketresearchreports.biz/sample/sample/1339577

The latest report Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)-Pipeline Review, H2 2017, outlays comprehensive information on the Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

View Sample PDF @ https://www.marketresearchreports.biz/reports/1339577/collagenase-3-matrix-metalloproteinase-13-or-mmp13-or-ec-3424-pipeline-review-h2-2017-market-research-reports.pdf

Scope

- The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
- The report reviews Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Have Any Query? Ask Our Expert @ https://www.marketresearchreports.biz/sample/enquiry/1339577

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)-Overview 6
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)-Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)-Therapeutics Assessment 12
Assessment by Mechanism of Action 12
Assessment by Route of Administration 13
Assessment by Molecule Type 15
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)-Companies Involved in Therapeutics Development 17
Paradigm Biopharmaceuticals Ltd 17
Pfizer Inc 17
Takeda Pharmaceutical Co Ltd 18
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)-Drug Profiles 19
pentosan polysulfate sodium-Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
PF-152-Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
Small Molecules to Inhibit MMP for Myocardial Infarction-Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Small Molecules to Inhibit MMP-13 for Osteoarthritis-Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation-Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
ZF-198-Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)-Dormant Products 28
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)-Discontinued Products 29
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)-Product Development Milestones 30
Featured News & Press Releases 30
Sep 19, 2017: Ethics Approval Received for Phase 2b Clinical Trial for Osteoarthritis 30
Sep 14, 2017: Paradigm Biopharmaceuticals: Significant momentum with Phase 2 Ross River Virus Clinical Trial 32
Sep 11, 2017: A Paradigm Shift In Treating Osteoarthritis Pain 33
Aug 09, 2017: Paradigm Successfully Doses First Participant In Phase 2 Ross River Virus Clinical Trial 35
Jul 10, 2017: Paradigm To Commence Phase 2 Ross River Virus Clinical Trial 36
May 16, 2017: Paradigms preclinical hay fever trial: peer-reviewed and published in leading scientific journal 36
Mar 23, 2017: Paradigm Biopharmaceuticals Announces Final participant treated in Phase 2 hay fever trial 37
Mar 07, 2017: The Australian Company Testing a Breakthrough Treatment for Ross River 38
Nov 22, 2016: Paradigm Phase 2 Hay Fever Trialgets Approval from Swedish MPA 39
Sep 16, 2016: Preclinical study underpins efficacy of Paradigms Rhinosul for hay fever treatment 40
Sep 07, 2016: Paradigms PPS as a potential breakthrough in t he treatment of viral arthritis and joint pain 41
Aug 19, 2016: Market update Paradigms PPS nasal spray to treat Allergic Rhinitis (Hay Fever) 42
May 25, 2016: Paradigm Biopharmaceuticals Provides Update on Rhinosul (pentosan polysulfate sodium) 43
Mar 02, 2016: Paradigm initiates second clinical trial site to investigate ZILOSUL as a treatment for bone bruising following Anterior Cruciate Ligament (ACL) injury 44
Feb 25, 2016: First participant in Paradigms clinical trial starts ZILOSUL treatment for bone bruising following Anterior Cruciate Ligament (ACL) injury 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.